Specification: |
The IUPAC name of L(-)-Bupivacaine is (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide. With the CAS registry number 27262-47-1, it is also named as Levobupivacaine. The classification codes are Anesthetics; Anesthetics, Local; Central Nervous System Agents; Central Nervous System Depressants; Drug / Therapeutic Agent; Peripheral Nervous System Agents; Sensory System Agents. It is highly toxic. And it will produce toxic nitrogen oxide fumes by heating, so the storage environment should be ventilate, low-temperature and dry. Keep L(-)-Bupivacaine separate from raw materials of food.
The other characteristics of this product can be summarized as: (1)ACD/LogP: 3.64; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 1.47; (4)ACD/LogD (pH 7.4): 3.15; (5)ACD/BCF (pH 5.5): 2.34; (6)ACD/BCF (pH 7.4): 111.54; (7)ACD/KOC (pH 5.5): 15.49; (8)ACD/KOC (pH 7.4): 739.57; (9)#H bond acceptors: 3; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 5; (12)Index of Refraction: 1.547; (13)Molar Refractivity: 88.62 cm3; (14)Molar Volume: 279.2 cm3; (15)Polarizability: 35.13×10-24 cm3; (16)Surface Tension: 41.5 dyne/cm; (17)Enthalpy of Vaporization: 67.78 kJ/mol; (18)Vapour Pressure: 2.24E-07 mmHg at 25°C; (19)Rotatable Bond Count: 5; (20)Tautomer Count: 2; (21)Exact Mass: 288.220164; (22)MonoIsotopic Mass: 288.220164; (23)Topological Polar Surface Area: 32.3; (24)Heavy Atom Count: 21.
Uses of L(-)-Bupivacaine: It is a local anaesthetic drug belonging to the amino amide group. And it is used for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children.
People can use the following data to convert to the molecule structure.
1. SMILES:O=C(Nc1c(cccc1C)C)[C@H]2N(CCCC)CCCC2
2. InChI:InChI=1/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1.
The following are the toxicity data which has been tested.
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
mouse |
LD50 |
intravenous |
9600ug/kg (9.6mg/kg) |
|
Acta Pharmacologica et Toxicologica. Vol. 31, Pg. 273, 1972. |
mouse |
LD50 |
subcutaneous |
100mg/kg (100mg/kg) |
|
Acta Pharmacologica et Toxicologica. Vol. 31, Pg. 273, 1972. |
rabbit |
LD50 |
intratracheal |
14mg/kg (14mg/kg) |
|
Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 78, 1976. |
rabbit |
LD50 |
parenteral |
> 120mg/kg (120mg/kg) |
|
Arzneimittel-Forschung. Drug Research. Vol. 26, Pg. 78, 1976. |
rabbit |
LDLo |
intravenous |
9700ug/kg (9.7mg/kg) |
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD |
Acta Pharmacologica et Toxicologica. Vol. 31, Pg. 273, 1972. |
rat |
LD50 |
intravenous |
7200ug/kg (7.2mg/kg) |
|
Acta Pharmacologica et Toxicologica. Vol. 31, Pg. 273, 1972. |
rat |
LD50 |
subcutaneous |
52mg/kg (52mg/kg) |
|
Acta Pharmacologica et Toxicologica. Vol. 31, Pg. 273, 1972.
|
|